Hanmi Pharmaceutical's Countmate targets the vial-based medication packaging market in Canada and the US. Hanmi ...
and XBRYKâ„¢ (denosumab-dssb; SB16; 120 mg vial), biosimilars referencing Prolia and Xgeva respectively. In addition, the FDA granted a provisional determination for both Ospomyv and Xbryk's ...
Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis and multiple myeloma/bone metastases from solid tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback